公开(公告)号：US20240254118A1

公开(公告)日：2024-08-01

申请号：US18391258

申请日：2023-12-20

Applicant: Gilead Sciences, Inc.

Inventor： Megan K. Armstrong ,  Elbert Chin ,  Chienhung Chou ,  Laurent P. Debien ,  Joshua D. Farr ,  Pancham Lal Gupta ,  Chao-I Hung ,  Michael L. Mitchell ,  Prasenjit K. Mukherjee ,  Shaina V. Nguyen ,  Gregory T. Notte ,  Daniel Roa ,  Adam J. Schrier ,  Zheng-Yu Yang

IPC: C07D471/04 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  C07D401/12 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  C07D401/12 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.

公开(公告)号：US20240376110A1

公开(公告)日：2024-11-14

申请号：US18663952

申请日：2024-05-14

Applicant: Gilead Sciences, Inc.

Inventor： Megan K. Armstrong ,  Elbert Chin ,  Chienhung Chou ,  Laurent P. Debien ,  Yifan Deng ,  Joshua D. Farr ,  Pancham Lal Gupta ,  Chao-I Hung ,  Benjamin J. June ,  Prasenjit K. Mukherjee ,  Shaina V. Nguyen ,  Gregory T. Notte ,  Daniel Roa ,  Adam J. Schrier ,  Katie A. Spence ,  Zheng-Yu Yang

IPC: C07D487/04 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D487/14 ,  C07D519/00

Abstract: The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.